Compare Eli Lilly And Co (LLY) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Plby Group Inc — how do they compare? Eli Lilly And Co trades at $1,175.8 (market cap $1.04T), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Eli Lilly And Co is far larger — about 8797.9× Plby Group Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Plby Group Inc for 24 Days on average.
| LLY | PLBY | |
|---|---|---|
Market Cap | $1.04T | $118.21M |
Volume | 3,064,878 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $2.71 |
52-Week Low | $799.57 | $0.99 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $1.09T | $263.80M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
PLBY Group trades at $0.97, down 4.5% today, with a bearish technical outlook despite analyst optimism. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses, though it remains unprofitable with negative equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
The stock presents a turnaround opportunity with strong analyst support (75% buy ratings) but carries significant risk from high debt levels and negative shareholder equity. Near-term catalysts depend on execution of the media and experiences strategy, while competitive pressures and cash flow volatility remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
